Demonstrates selective hydrosilylation outcomes in novel hydrosilylation catalysts, suggesting improved functionalization methods.
Selective hydrosilylation of ω-hydroxyalkenes is achieved using 2-methacryloyloxyethyl phosphorylcholine (MPC)-protected ruthenium nanoparticles ((PC-SH) Ru NPs). The MPC-derived surface suppresses O-silylation, enabling unprecedented C=C functionalisation unattainable with other Ru catalysts. (PC-SH)...
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: